FDA Expands Dapagliflozin Label to Include Reducing Risk of CV Death in Heart Failure

Announced just more than a year after AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular death and HF hospitalizations for dapagliflozin based on results of the phase 3 DELIVER trial.

Related Keywords

United States ,America ,Campbellp Dapagliflozin ,Stephen Greene ,Drug Administration ,European Society Of Cardiology ,Duke University School Of Medicine ,Astrazeneca ,Heart Failure Society Of America ,European Society ,Ruud Dobber ,Biopharmaceuticals Business Unit ,Heart Failure Society ,Get With The Guidelines Heart Failure ,Duke University School ,